Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
- PMID: 26939706
- DOI: 10.1158/1535-7163.MCT-15-0730
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Abstract
BCL-2 family proteins dictate survival of human multiple myeloma cells, making them attractive drug targets. Indeed, multiple myeloma cells are sensitive to antagonists that selectively target prosurvival proteins such as BCL-2/BCL-XL (ABT-737 and ABT-263/navitoclax) or BCL-2 only (ABT-199/GDC-0199/venetoclax). Resistance to these three drugs is mediated by expression of MCL-1. However, given the selectivity profile of venetoclax it is unclear whether coexpression of BCL-XL also affects antitumor responses to venetoclax in multiple myeloma. In multiple myeloma cell lines (n = 21), BCL-2 is expressed but sensitivity to venetoclax correlated with high BCL-2 and low BCL-XL or MCL-1 expression. Multiple myeloma cells that coexpress BCL-2 and BCL-XL were resistant to venetoclax but sensitive to a BCL-XL-selective inhibitor (A-1155463). Multiple myeloma xenograft models that coexpressed BCL-XL or MCL-1 with BCL-2 were also resistant to venetoclax. Resistance to venetoclax was mitigated by cotreatment with bortezomib in xenografts that coexpressed BCL-2 and MCL-1 due to upregulation of NOXA, a proapoptotic factor that neutralizes MCL-1. In contrast, xenografts that expressed BCL-XL, MCL-1, and BCL-2 were more sensitive to the combination of bortezomib with a BCL-XL selective inhibitor (A-1331852) but not with venetoclax cotreatment when compared with monotherapies. IHC of multiple myeloma patient bone marrow biopsies and aspirates (n = 95) revealed high levels of BCL-2 and BCL-XL in 62% and 43% of evaluable samples, respectively, while 34% were characterized as BCL-2(High)/BCL-XL (Low) In addition to MCL-1, our data suggest that BCL-XL may also be a potential resistance factor to venetoclax monotherapy and in combination with bortezomib. Mol Cancer Ther; 15(5); 1132-44. ©2016 AACR.
©2016 American Association for Cancer Research.
Similar articles
-
Potential mechanisms of resistance to venetoclax and strategies to circumvent it.BMC Cancer. 2017 Jun 2;17(1):399. doi: 10.1186/s12885-017-3383-5. BMC Cancer. 2017. PMID: 28578655 Free PMC article.
-
Targeting Bcl-2 for the treatment of multiple myeloma.Leukemia. 2018 Sep;32(9):1899-1907. doi: 10.1038/s41375-018-0223-9. Epub 2018 Aug 3. Leukemia. 2018. PMID: 30076373 Review.
-
Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.Cell Death Differ. 2019 Jul;26(7):1316-1331. doi: 10.1038/s41418-018-0209-1. Epub 2018 Nov 23. Cell Death Differ. 2019. PMID: 30470795 Free PMC article.
-
Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).Blood Cancer J. 2015 Nov 13;5(11):e368. doi: 10.1038/bcj.2015.88. Blood Cancer J. 2015. PMID: 26565405 Free PMC article.
-
Pathways and mechanisms of venetoclax resistance.Leuk Lymphoma. 2017 Sep;58(9):1-17. doi: 10.1080/10428194.2017.1283032. Epub 2017 Jan 31. Leuk Lymphoma. 2017. PMID: 28140720 Free PMC article. Review.
Cited by
-
Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives.Cancers (Basel). 2021 Mar 14;13(6):1292. doi: 10.3390/cancers13061292. Cancers (Basel). 2021. PMID: 33799470 Free PMC article. Review.
-
Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance.Cancers (Basel). 2021 Mar 16;13(6):1336. doi: 10.3390/cancers13061336. Cancers (Basel). 2021. PMID: 33809580 Free PMC article. Review.
-
Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis.Cell Death Dis. 2018 Sep 24;9(10):986. doi: 10.1038/s41419-018-1040-9. Cell Death Dis. 2018. PMID: 30250075 Free PMC article.
-
A systematic review of the therapeutic effects of resveratrol in combination with 5-fluorouracil during colorectal cancer treatment: with a special focus on the oxidant, apoptotic, and anti-inflammatory activities.Cancer Cell Int. 2022 Apr 2;22(1):142. doi: 10.1186/s12935-022-02561-7. Cancer Cell Int. 2022. PMID: 35366874 Free PMC article. Review.
-
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor.Front Oncol. 2021 Sep 30;11:716751. doi: 10.3389/fonc.2021.716751. eCollection 2021. Front Oncol. 2021. PMID: 34660279 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials